BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

Rhea-AI Summary

BioXcel Therapeutics (Nasdaq: BTAI) will host a virtual event on April 23, 2026 at 2:00 p.m. ET to discuss its commercial launch plan for IGALMI in the at-home setting.

The presentation will outline launch strategy ahead of the November 14, 2026 PDUFA target action date and follows a market opportunity assessment that identified up to 86 million annual addressable episodes of at-home acute agitation in the U.S.

News Market Reaction – BTAI

+7.48%

18 alerts

+7.48% Session close to close

+12.1% Peak in 1 hr 54 min

$33.98M Market Cap

0.7x Rel. Volume

In the Apr 17 session, BTAI gained 7.48%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.1% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.5% in the session following this news. A strong positive reaction aligns with Bio...

Analysis

The stock moved +7.5% in the session following this news. A strong positive reaction aligns with BioXcel’s ongoing pivot toward IGALMI’s at‑home opportunity. The company previously highlighted up to 86 million addressable annual episodes and has an accepted sNDA with a Nov 14 PDUFA date. Past history shows mixed reactions to positive milestones, so any outsized move could face volatility if financing needs, execution risks, or prior divergence patterns resurface in investor focus.

Key Figures

PDUFA target date: November 14 Addressable annual episodes: 86 million Virtual event duration: 1 hour

3 metrics

PDUFA target date November 14 Target action date for IGALMI at-home setting

Addressable annual episodes 86 million Estimated acute agitation episodes in U.S. at-home setting

Virtual event duration 1 hour Webcast from 2:00 to 3:00 p.m. ET on April 23

Historical Context

5 past events · Latest: Apr 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 08	ASR trial enrollment	Positive	+0.9%	First patients enrolled in DoW‑funded Phase 2a ASR trial using BXCL501.
Apr 01	IGALMI sNDA accepted	Positive	-9.0%	FDA acceptance of IGALMI sNDA for at‑home use with set PDUFA date.
Mar 27	FY 2025 earnings	Neutral	-8.0%	Reported 2025 financials and cash alongside prep for potential at‑home launch.
Mar 11	Offering closed	Negative	-1.3%	Closed $8.0M registered direct offering with new warrants and amended terms.
Mar 10	Offering announced	Negative	-10.4%	Announced ~$8.0M registered direct equity and warrant financing to an investor.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive regulatory and clinical milestones have sometimes seen negative price reactions, while financing news has generally aligned with downside moves.

Recent Company History

Over the last six weeks, BioXcel has focused on advancing BXCL501/IGALMI toward at‑home use. On Mar 10–11, the company announced and closed an $8.0M registered direct offering, which coincided with negative price reactions. The Mar 27 earnings update highlighted modest IGALMI revenue and continued losses as launch planning progressed. On Apr 1, FDA acceptance of the IGALMI sNDA with a Nov 14, 2026 PDUFA date led to a sharp selloff, and on Apr 8, enrollment of a DoW‑funded ASR study saw a small gain. Today’s event-focused announcement fits this ongoing commercialization build-out.

Key Terms

pdufa, acute agitation, bipolar disorders, schizophrenia

4 terms

pdufa regulatory

"ahead of November 14 PDUFA target action date of IGALMI"

PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.

acute agitation medical

"for the treatment of acute agitation associated with bipolar disorders"

Acute agitation is a sudden, intense episode of restlessness, anxiety or aggressive behavior that can include pacing, shouting, threats or physical resistance and usually needs quick medical or security attention. For investors, it matters because reports of acute agitation in clinical trials or post-market safety data can influence regulators, product labels, prescribing habits and public perception—much like a sudden safety recall can change a product’s commercial outlook.

bipolar disorders medical

"acute agitation associated with bipolar disorders and schizophrenia"

A group of mental health conditions marked by repeated swings in mood, energy and activity levels that range from high, restless ‘manic’ states to low, slowed ‘depressive’ states; these mood shifts can disrupt work, relationships and daily functioning. Investors care because the condition drives demand for medications, therapies and support services, affects workforce productivity and disability costs, and shapes risk and opportunity for pharma, insurers and healthcare providers — like a thermostat that unpredictably flips between hot and cold, changing energy needs.

schizophrenia medical

"acute agitation associated with bipolar disorders and schizophrenia"

A chronic brain disorder that changes how a person thinks, perceives reality, feels and interacts with others, often causing hallucinations, false beliefs and trouble organizing thoughts or daily life. It matters to investors because the condition creates demand for long‑term treatments, diagnostics and support services; developing effective therapies can be costly, risky and highly regulated, but successful drugs or devices can open large, steady markets—think of it like fixing a deep, complex software bug that many users rely on.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live event to be held on Thursday, April 23, at 2:00 p.m. ET 

Company focused on advancing launch strategy ahead of November 14 PDUFA target action date

NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced it will host a virtual event on Thursday, April 23, from 2:00 to 3:00 p.m. ET. 

The event will center on the Company’s ongoing launch strategy initiatives ahead of the November 14 PDUFA target action date of IGALMI® for the treatment of acute agitation associated with bipolar disorders and schizophrenia in the at-home setting. A presentation by Mark Pavao, the Company’s Interim Chief Commercial Officer, will outline key elements of the Company’s commercial launch plan, building on insights from the recently completed market opportunity assessment. Analyses from the assessment identified up to 86 million addressable annual episodes of acute agitation in the at-home setting in the United States, underscoring the substantial market opportunity for IGALMI. 

The event will be moderated by Michael King, Managing Director at Rodman & Renshaw and covering analyst for BioXcel Therapeutics.

Webcast Details: 

To register for the webcast, click here. A replay of the event will be available on the BioXcel Therapeutics website following the live presentation.  

Attendees may submit questions via written Q&A during the event. Attendees are encouraged to log in approximately 10 minutes prior to the scheduled start time.  

About IGALMI^® (dexmedetomidine) sublingual film

INDICATION

IGALMI^® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children.

IMPORTANT SAFETY INFORMATION 

IGALMI can cause serious side effects, including: 

• Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint. 
• Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations. 
• Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI. 
• Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours. 
  
  

The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing. 

These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects. 

Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids. 

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or medinfo@bioxceltherapeutics.com. 

Please see full prescribing information at Igalmi.com. 

About BXCL501

Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI^® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer’s dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the approval of IGALMI for use in the at-home setting; bringing IGALMI^® directly to patients in the at-home setting; the approval of IGALMI for use in the at-home setting; bringing IGALMI^® directly to patients in the at-home setting; use of IGALMI in approximately 70% of schizophrenia and bipolar disorder patients, regardless of agitation severity; prescribers using IGALMI either alone or in combination with existing off-label treatments for acute agitation; IGALMI replacing benzodiazepines, which may cause dependence; broad formulary coverage of IGALMI with standard adjudication controls; patients with schizophrenia and bipolar disorder using IGALMI in approximately 80% of their acute agitation episodes; evaluating go-to-market options; reimagining existing medicines and accelerating the development of innovative therapies; transforming the standard of care in neuropsychiatry and improve lives around the world. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI^®, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company’s total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI^® or the Company’s product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI^®; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at and the Investors section of the Company’s website at. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Contact Information: 

Corporate/Investors 
Russo Partners 
Nic Johnson 
nic.johnson@russopartnersllc.com  
1.303.482.6405 

Media 
Russo Partners 
David Schull 
david.schull@russopartnersllc.com  
1.858.717.2310 

Source: BioXcel Therapeutics, Inc. 

FAQ

When is BioXcel Therapeutics (BTAI) hosting the virtual event to discuss IGALMI launch plans?

The virtual event is scheduled for April 23, 2026 at 2:00 p.m. ET and will run one hour. According to the company, the session will include a presentation by Interim Chief Commercial Officer Mark Pavao outlining launch strategy ahead of the November 14 PDUFA date.

What will BioXcel (BTAI) discuss about IGALMI at the April 23, 2026 webcast?

The webcast will outline the company’s commercial launch plan and market insights for at-home use of IGALMI. According to the company, the presentation builds on a market opportunity assessment identifying up to 86 million addressable annual at-home agitation episodes in the U.S.

Who is presenting and moderating the BioXcel (BTAI) April 23, 2026 virtual event?

Mark Pavao, Interim Chief Commercial Officer, will present; Michael King of Rodman & Renshaw will moderate. According to the company, attendees may submit written Q&A during the event and a replay will be available afterward on the company website.

How does BioXcel describe the market opportunity for IGALMI in the at-home setting?

The company’s market assessment identified up to 86 million addressable annual episodes of acute agitation in the U.S. at home. According to the company, this figure underscores a substantial potential market opportunity for IGALMI ahead of the November 14 PDUFA target date.

How can investors access the BioXcel (BTAI) April 23, 2026 webcast and replay?

Investors can register for the live webcast via the company’s webcast registration link and view a replay on the company website after the presentation. According to the company, attendees are encouraged to log in about 10 minutes early and may submit written Q&A during the event.